Durata Therapeutics (NASDAQ: DRTX) and Abeona Therapeutics (NASDAQ:ABEO) are both biotechnology & medical research – nec companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings and analyst recommendations.

Earnings & Valuation

This table compares Durata Therapeutics and Abeona Therapeutics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Durata Therapeutics N/A N/A N/A ($2.76) N/A
Abeona Therapeutics $890,000.00 812.08 -$21.87 million ($0.66) -23.41

Durata Therapeutics has higher earnings, but lower revenue than Abeona Therapeutics. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Durata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

42.0% of Abeona Therapeutics shares are owned by institutional investors. 6.8% of Abeona Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Durata Therapeutics and Abeona Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Durata Therapeutics N/A N/A N/A
Abeona Therapeutics -2,946.58% -27.69% -25.32%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Durata Therapeutics and Abeona Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Durata Therapeutics 0 0 0 0 N/A
Abeona Therapeutics 0 0 9 0 3.00

Abeona Therapeutics has a consensus price target of $27.00, indicating a potential upside of 74.76%.

Summary

Abeona Therapeutics beats Durata Therapeutics on 5 of the 8 factors compared between the two stocks.

About Durata Therapeutics

Durata Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of therapeutics for patients with infectious diseases and acute illnesses. The Company enroll and dose patients in two global Phase III clinical trials with its product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections (abSSSI). Dalbavancin is an intravenous antibiotic product candidate designed for once-weekly dosing. In addition to abSSSI, the Company focuses on the development of dalbavancin for additional indications, including osteomyelitis, diabetic foot infection and pneumonia. As of December 31, 2011, Dalbavancin had already completed three Phase III clinical trials, in which more than 1,000 patients in total received dalbavancin.

About Abeona Therapeutics

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa, ABO-301 (AAV-FANCC) for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. The Company also has a plasma-based protein therapy pipeline, including alpha-1 protease inhibitor (SDF Alpha) for inherited COPD, using its proprietary Salt Diafiltration ethanol-free process.

Receive News & Ratings for Durata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Durata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.